Navigation Links
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
Date:6/23/2009

CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ -- Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant decrease of epileptic activity in mice pre-treated with Kainic acid.

"We are pleased with these initial results that confirm the predicted efficacy of BVA-601 and encourage us to further test and develop this compound in a disease area where there is a need for new, patient-friendly therapies," said Aris Persidis, Ph.D., President of Biovista. "This successful repositioning builds on our previously reported success with BVA-101 in multiple sclerosis, expanding our CNS portfolio. At the present time we are exploring all options available to us, including the further co-development with a pharmaceutical company and the licensing of the IP to a generics company," added Dr. Persidis.

For a non-confidential information pack on BVA-601, contact Biovista at info@biovista.com.

About Biovista's BVA-601 trial in the Kainic acid model of epilepsy

Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures may be transient signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. Epilepsy is one of the world's oldest recognized conditions, affecting around 50 million people worldwide. Fear, discrimination and social stigma have surrounded epilepsy for centuries. Some of the stigma continues today in many countries impacting the quality of life of people with the
'/>"/>

SOURCE Biovista Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Dragon Pharma Announces Results of 2009 Annual General Meeting
4. Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
5. Isolagen, Inc. Announces Receipt of Interim Order from Bankruptcy Court Approving DIP Motion
6. Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R)
7. Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities
8. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
9. Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
10. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
11. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
(Date:11/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... pharmaceutical company, today announced it has submitted an additional ... and Drug Administration (FDA), which brings the Company,s total ... eighteen submissions now pending at the FDA. ... the Company, commented, "Our team here at IGI has ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... , November 24, 2014   ... on ScienceDirect   Elsevier , a world-leading ... is pleased to announce the launch of the latest title ... Current Opinion in Food Science . ... provide specialists with a new platform to keep up-to-date with ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... BioSpace, the leading biotech,job board and life ... and pharmaceutical job seekers to the first BioSpace ... The BioSpace Career Fair attracted a steady flow ... from around southern California. The event offered a ...
... of ... DEERFIELD, Ill., Feb. 11 Baxter Healthcare,Corporation is providing ... 10 and 30mL multi-dose vial voluntary recall of,nine lots, which ... in reports of adverse reactions that may be associated with ...
... Phlo,Corporation,s ("Phlo"") (OTC: PHLC) press release of December 27, ... City Account,Base," an affiliate of Phlo (the "Company") announced ... has sold and delivered,AQISS(TM) to the following initial retail ... roll out. AQISS(TM) is currently available for sale to ...
Cached Biology Technology:BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates 2Baxter Provides Update on Heparin Reactions 2Baxter Provides Update on Heparin Reactions 3Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out 2
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
(Date:11/3/2014)... study published in this month,s Proceedings ... activity of a recently discovered communication molecule of the ... been known to limit inflammation and the current study ... inhibits the ability of the immune system to recognize ... underlies IL-37,s effect on the immune system now allows ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... the world,s rarest amphibians from extinction, one hundred Kihansi spray ... reared at the Bronx Zoo and The Toledo Zoo working ... Bank. The toads now reside at a new, state-of ... with the eventual goal of reintroducing the tiny amphibians into ...
... medetomidine has proved effective in preventing fouling of ship bottoms. ... gene that causes the barnacle to react to the substance, ... gentle both on barnacles and on the environment. Fouling ... private leisure craft as well as large cargo ships. The ...
... 2010 (BRONX, NY) Albert Einstein College of Medicine ... Institutes of Health,s (NIH) Nathan Shock Centers of Excellence in ... centers nationwide provides leadership in the pursuit of basic research ... million, five-year grant from the NIH,s National Institute on Aging. ...
Cached Biology News:Kihansi spray toads make historic return to Tanzania 2Kihansi spray toads make historic return to Tanzania 3Gene that causes barnacles to avoid ship hulls identified 2Einstein designated an NIH Center of Excellence for aging research 2Einstein designated an NIH Center of Excellence for aging research 3Einstein designated an NIH Center of Excellence for aging research 4
... Minis 300V power supply (Cat. No. Minis ... sufficient for SDS-PAGE, and native PAGE applications. ... of terminator pairs can be used simultaneously. ... individuals to have his/her own power supply ...
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: